Karyopharm Therapeutics
KPTI
KPTI
143 hedge funds and large institutions have $347M invested in Karyopharm Therapeutics in 2021 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 51 increasing their positions, 46 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
143
Holders Change
+9
Holders Change %
+6.72%
% of All Funds
2.21%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
29
Increased
51
Reduced
46
Closed
17
Calls
$4.62M
Puts
$10.3M
Net Calls
-$5.68M
Net Calls Change
+$171K
Top Buyers
| 1 |
Millennium Management
New York
|
+$9.78M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$3.75M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$3.01M |
| 4 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$1.93M |
| 5 |
JPMorgan Chase & Co
New York
|
+$1.79M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$16.1M |
| 2 |
Morgan Stanley
New York
|
-$5.32M |
| 3 |
Two Sigma Advisers
New York
|
-$4.21M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$3.82M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$2.92M |
